<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625284</url>
  </required_header>
  <id_info>
    <org_study_id>Clinical protocol FUCO 02</org_study_id>
    <nct_id>NCT03625284</nct_id>
  </id_info>
  <brief_title>Oral Dietary Fucoxanthin Rich Supplement for Liver Health</brief_title>
  <official_title>Oral Dietary Fucoxanthin Rich Supplement for Liver Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Algatechnologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Algatechnologies Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blind, placebo-controlled study testing the hypothesis that oral dietary supplement rich with
      fucoxanthin will decrease biochemical clinical markers related to liver health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Six month supplementation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 10, 2018</start_date>
  <completion_date type="Anticipated">December 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver function test: Serum Alanine transaminase (ALT)</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline of liver enzymes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver function test: Aspartate transaminase (AST)</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline of liver enzymes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function test:Blood gamma-glutamyl transferase (GGT)</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function test:Blood albumin</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function test: Blood bilirubin</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic steatosis</measure>
    <time_frame>0, 24 week</time_frame>
    <description>Change from baseline by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipid profile</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline total cholesterol, triglycerides, low density lipoprotein (LDL) (HDL) fractions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose status</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline of HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function test: serum creatinine</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function test: Glomerular Filtration Rate(GFR)</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function test: Blood Urea Nitrogen</measure>
    <time_frame>week 0,12,24</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary supplement level in the blood</measure>
    <time_frame>week 0,6 or 12,24</time_frame>
    <description>Determination of Fucoxanthin metabolite in plasma by LC-MS/MS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non Alcoholic Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Fucovital</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsules of a dietary supplement rich with fucoxanthin from microalgae extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsules of an edible oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Edible oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FucoVital</intervention_name>
    <description>Microalgae oil extract</description>
    <arm_group_label>Fucovital</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>fucoxanthin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults &gt; 18 years

          -  Willing to sign an informed consent to participate in the study.

          -  Non-smokers.

          -  Blood results above the normal range in hepatic function testing consisting of panels
             containing ALT, AST, ALP, total bilirubin and albumin and abdominal ultrasonography.

          -  Over-weight (BMI â‰¥ 27 kg/m2) who fulfill the criteria of the National Cholesterol
             Education Program (NCEP) metabolic syndrome.

        Exclusion Criteria:

          -  Pregnancy.

          -  Presence of gastrointestinal or mental disorders, diabetes mellitus, alcohol abuse,
             weight-loss treatment, bariatric surgery, unusual diets (vegetarian, vegan), daily
             usage of antioxidants dietary supplements at the last 4 months (for subjects in stage
             2 of the study).

          -  Serious medical conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haim Shirin, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director Institute of Gastroenterolgy, Liver Diseases and Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tair Lapidot, Dr</last_name>
    <phone>+972548095209</phone>
    <email>tair@algatech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marina Beder</last_name>
    <email>marinabe@asaf.health.gov.il</email>
  </overall_contact_backup>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 12, 2018</last_update_submitted>
  <last_update_submitted_qc>August 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fucoxanthin</keyword>
  <keyword>microalgae</keyword>
  <keyword>non alcoholic fatty liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

